Navigation Links
Stereotaxis to Report First Quarter 2012 Financial Results on May 8, 2012

ST. LOUIS, May 2, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today announced that it will release financial results for the first quarter 2012 on Tuesday, May 8, 2012 before the opening of the U.S. financial markets.  The Company will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's results and corporate developments.Conference call details:Date:Tuesday, May 8, 2012Time:8:30 a.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9772Web cast:www.stereotaxis.comTo access an audio replay of the call:Replay (U.S.):800-406-7325Replay (International):303-590-3030Replay Passcode:4536824About StereotaxisStereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables. 

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit and

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Reports 2011 Financial Results; Provides 2012 Milestones
2. Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012
3. Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers
4. Stereotaxis to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Stereotaxis Reports Third Quarter Financial Results
6. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
7. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
8. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
9. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
10. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... of Clinical Services, Education and Human Resources will be presenting ... Oncology Drugs: Health Plan Strategies for a Dynamic Market" on ... Fenrick , a consultant with the Cambridge Advisory Group, where ... The webinar will discuss the rapid growth ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
(Date:11/24/2015)... , November 24, 2015 ... CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... going to grow at the fastest rates? This ... assessing data, trends, opportunities and prospects there. ,  ,Our ... the most lucrative areas in the industry and the ...
Breaking Medicine Technology:
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Reactor System. Brillouin is the developer of renewable energy technologies capable of producing ... reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor core ...
(Date:11/24/2015)... Indianapolis, IN (PRWEB) , ... November 24, 2015 ... ... employee benefits advisory organization, is pleased to welcome Winter-Dent & Company as its ... strive from day one to become a client's most trusted advisor regardless of ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American ... support their local poison centers through donations on Tuesday, Dec. 1, 2015. Since ... “a day that inspires people to collaborate in improving their local communities and ...
(Date:11/24/2015)... MI (PRWEB) , ... November 24, 2015 , ... Serenity ... released a series of recent video interviews with some of the staff members at ... at the residential treatment facility, as well as some of the things that make ...
Breaking Medicine News(10 mins):